Omnicell has raised its full-year 2026 non-GAAP earnings per share and EBITDA guidance following strong second-quarter results, though the company warns that rising memory chip costs and a younger installed base could delay the rollout of its new Titan XT platform. The move highlights a tension between near-term cost discipline and longer-term structural headwinds in the autonomous pharmacy sector.
In the second quarter of 2026, Omnicell reported non-GAAP EBITDA of $67 million, a figure that included a one-time $15 million refund of previously paid International Emergency Economic Powers Act tariffs. Excluding that refund, the company's EBITDA would have been $52 million, which management noted remained above the midpoint of prior guidance. Citing revenue mix, cost control, and operating efficiency, Omnicell lifted its full-year 2026 non-GAAP EBITDA guidance to $175-$185 million and non-GAAP EPS guidance to $2.15-$2.30. The Zacks Consensus Estimate for 2026 EPS has remained steady at $2.15 over the past 30 days, while the consensus revenue estimate stands at $1.24 billion, representing a 4.4% increase from the year-ago figure.
The company's strategic focus remains on expanding its enterprise medication-management platform, specifically through the adoption of Titan XT and OmniSphere. Management stated that customer engagement around these products remained high, with the product-bookings pipeline exiting the quarter larger than in recent years. Omnicell secured its first competitive Titan XT conversion win of 2026 alongside other solutions. Service revenues reached $137 million in the second quarter of 2026, up from $127 million in the same period a year earlier, supporting the company's push for a more predictable recurring revenue base through cloud-based offerings and software subscriptions.
However, input cost volatility presents a significant margin risk. The company expects an imbalanced supply-demand environment for memory chips to add approximately $6 million in incremental costs during the second half of 2026, a figure management described as about five times the beginning-of-year cost estimate. This increase is expected to reduce full-year 2026 consolidated gross margin by about 50 basis points and product gross margin by about 80 basis points. Unlike the one-time tariff refund that boosted the second quarter, these chip-related costs represent a recurring operational challenge.
Furthermore, the refresh cycle for Titan XT may proceed more slowly than previous generations. Management noted that the current XT installed base is younger than the G Series base was when customers previously transitioned to XT. This younger fleet reduces the immediate urgency for existing customers to replace functioning equipment. While Titan XT is scheduled for shipment in the second half of 2026, Omnicell acknowledged that customers often take quarters or years to approve large capital projects, a process that could defer revenues associated with the new platform launch.
Over the past year, Omnicell stock has risen 24.2%, outperforming the industry's 5.8% decline but lagging behind the S&P 500 composite's 18.6% growth. The healthcare technology company currently holds a market capitalization of $1.63 billion and an earnings yield of 6%, compared to the industry's negative 1.8% yield. Zacks Investment Research maintains a Zacks Rank #3 (Hold) for Omnicell, while noting that higher-ranked peers in the medical space include Phibro Animal Health, Abbott Laboratories, and Globus Medical.